drugset / Trial / NCT00334776
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 2
Completed
6 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
Timeline
- Start
- 2003-10
- Primary completion
- 2005-06
- Completion
- 2005-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DISOMOTIDE | Peptide | — | Other |
| Subject | MART-1 | Peptide | — | Other |
| Subject | autologous dendritic cells | Cell therapy | — | Other |
| Subject | tyrosinase peptide | Peptide | — | Other |